Biocracked
Approach 4, conceptual metaphor, with palette D, bold color field.

A single cross-section of a rusted, mineral-crusted copper pipe stands upright at center, shot from a slightly low three-quarter angle with a shallow depth of field. Its inner wall is thickly lined with chalky white-orange scale that narrows the bore to a small opening. One side of the buildup is hard and crystalline, while the other side is softer and still forming. A thin, clean ribbon of electric green liquid (#00e676) runs through the remaining channel, a subtle accent. The backdrop is a seamless saturated mustard-yellow field. Hard, directional studio light from upper left casts a crisp, short shadow to the right. Textures are tactile and macro-sharp, with visible grit and flaking. The mood is calm, analytical and slightly cautionary.
Supplements

The Vitamin That Slowed Artery Calcification for 2 Years

Nova Chen · · 4 min read

A cheap, widely sold supplement just did something in a randomized trial that most supplements never manage: it measurably slowed the buildup of calcium in the coronary arteries of people who already have heart disease. The catch, and there is one, is that nobody yet knows whether it prevents a single heart attack.

The supplement is vitamin K2 as menaquinone-7 (MK-7). The trial is VitaK-CAC, published in JAMA Cardiology in 2026.

The Headline Numbers

Participants had symptomatic coronary artery disease (CAD) and a baseline coronary artery calcium (CAC) score between 50 and 400 Agatston units (AU). They took either 360 µg of MK-7 daily or an identical placebo for two years. Median CAC scores in each group moved like this:

Group Baseline Year 1 Year 2
Placebo 145 AU 173 AU 214 AU
MK-7 (360 µg/day) 135 AU 150 AU 184 AU

That works out to a median rise of about 49 AU on MK-7 versus about 69 AU on placebo. The between-group difference was statistically significant (P = .02), including after adjustment for covariates. Calcium mass, a second CT-based measure, showed a similar result.

Calcification still progressed in the MK-7 group. It just progressed more slowly.

Who Was Studied

The researchers randomized 180 patients, 90 per group, at one university hospital and one community hospital in the Netherlands. The analysis covered 85 patients on MK-7 and 82 on placebo.

  • Age: median 59 years (MK-7) and 61 years (placebo)
  • Sex: 42% female in both groups
  • Condition: symptomatic atherosclerotic CAD with moderate calcium (CAC 50-400 AU)
  • Baseline balance: the two groups were comparable

This was a relatively young, middle-aged group with established but not extreme calcification. Results may not carry over to people with very high CAC, no symptoms, or kidney disease.

It Wasn't Just Calcium Scores: The Plaque Detail

The most interesting part of the paper is where the effect seemed to come from. Participants also had CT angiography, which lets researchers look at plaque type. The rise in CAC score correlated with the number of noncalcified plaques that became partially calcified during the study (R² = 0.17; P = .04).

The authors' interpretation is that MK-7 may slow calcification in noncalcified plaques. The correlation is modest, since an R² of 0.17 means most of the variation is explained by other factors. It points to a plausible mechanism rather than proving one.

There is also a biological sanity check. Plasma MK-7 rose from a median of 0.50 µg/L to 6.56 µg/L in the treatment group (P < .001), so participants were taking the supplement and absorbing it. That matters because adherence problems can quietly sink supplement trials.

Safety

The authors reported no significant adverse effects. For a two-year trial of a supplement, that is reassuring, though a trial of this size can't rule out rare problems.

What We Don't Know

This is where the headline needs honest limits.

  • The clinical meaning is unproven. The authors say the significance of the finding "in terms of plaque stability remains to be determined." Slower calcification is a imaging result, not a reduction in heart attacks, strokes, or death. Calcification is also a complicated marker. Some calcified plaque may be more stable than soft plaque, so slower calcification is not automatically good.
  • The absolute difference is modest. About 20 AU separated the groups' median increases over two years.
  • The trial was not large. About 167 analyzed patients is enough to detect a CAC difference but not clinical events.
  • The timeline was long and interrupted. Data were collected from 2012 through 2022 "with a few interruptions."
  • There is an industry link. Prof Leon Schurgers reported receiving grants from Gnosis by Lesaffre, a maker of MK-7, and holding shares in Coagulation Profile, both described as outside the submitted work. That doesn't invalidate the results, but it is worth knowing. An accompanying commentary in the same issue of the journal also weighs in on the findings.

Practical Takeaways

Dose: The trial used 360 µg of MK-7 per day. That is the only dose with this evidence behind it, and it is higher than the amounts in many multivitamins.

Form: MK-7, not MK-4. The study tested menaquinone-7 only. It did not test MK-4 or vitamin K1, so these results shouldn't be assumed to apply to them. It also tested MK-7 against placebo on its own, not as part of a combination formula.

Timing: The abstract doesn't specify when participants took it. Vitamin K is fat-soluble, so taking it with a meal containing some fat is the common-sense approach. That is general guidance, not something this trial tested.

Who it might be relevant for: The evidence applies to people like those enrolled, meaning middle-aged adults with symptomatic CAD and moderate coronary calcification. If that describes you, it's a reasonable topic to raise with your cardiologist. It shouldn't replace statins, blood pressure control, or other proven therapy.

Who should skip it, or ask first:

  • Anyone on warfarin or another vitamin K antagonist. Vitamin K directly affects how these drugs work, and supplementing can change your INR. Never start MK-7 without your prescriber's involvement.
  • People on other anticoagulants or with a clotting history, who should check with their doctor first.
  • Anyone hoping it will "reverse" calcification. The trial showed slower progression, not reduction.
  • People without heart disease. This trial doesn't tell us whether MK-7 helps healthy adults.

The Bottom Line

VitaK-CAC is a well-designed, placebo-controlled test of a plausible idea, and it produced a statistically significant slowing of coronary calcification with a good safety record. It is encouraging and mechanistically interesting, especially the signal in noncalcified plaques. But it is a surrogate-marker result from a modest trial, with a conflict-of-interest disclosure worth noting. Until larger studies show fewer cardiac events, MK-7 is a promising add-on to discuss with your doctor, not a heart-disease fix.

Source: Vossen LM, de Leeuw PW, Schurgers LJ, et al. Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. JAMA Cardiology. 2026;11(8):719-726. doi:10.1001/jamacardio.2026.1279. ClinicalTrials.gov: NCT01002157. PubMed.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

NC

Written by

Nova Chen

Nova Chen writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: conceptual metaphor. Palette: D, bold color field.

A single cracked ceramic-white bone-shaped column, like a femur section, stands upright at the center of a saturated mustard-yellow seamless backdrop. A thin, clean hairline fracture runs through its middle. Beside it, a small golden-amber glass dropper bottle sits tipped, with one droplet suspended just above the bone and not touching it, which suggests extra vitamin D that makes no difference. The camera is at a low three-quarter angle with a shallow depth of field. Hard, directional studio light from the upper left casts a crisp, long shadow across the yellow floor. The porous bone texture is visible in fine detail. A tiny electric green (#00e676) droplet reflection glints on the glass. The mood is skeptical, cool-headed and editorial.
longevity

High-Dose Vitamin D for Bones? A 5-Year Trial Says No

BY DR. SYNAPSE ·

Taking extra vitamin D to keep your bones strong? A five-year randomized trial in 2,495 older Finns found that neither 1,600 nor 3,200 IU/day reduced fractures compared with placebo. Oddly, the 1,600 IU group had more fractures (HR 1.52), though the higher dose showed no such effect, which suggests chance may be at play. Participants already had sufficient vitamin D at baseline, so the results may not apply to people who are deficient. Here is what the study found, what its limits are, and what to do before buying another bottle.

Approach: conceptual metaphor. Palette: bold color field (D).

Subject: a clear glass tube-shaped pipe, cut in cross-section, sitting on a saturated mustard-yellow backdrop. Its inner wall is lined with chalky, white mineral crust that narrows the opening on one end and thins out toward the other, showing progression slowing. A single thin electric green thread runs through the clear center as a small accent.

Camera: low three-quarter angle, shallow depth of field, macro lens, with the narrowed end sharp in the foreground and the clear end softly blurred behind.

Lighting: bright, soft studio light from the upper left with crisp highlights on the glass and a clean, warm-grey shadow cast on the yellow surface. No blue cast.

Mood: calm, precise, cautiously optimistic. The mineral texture should look real, gritty and crystalline, not cartoonish. No text or labels.
supplements

720 mcg Vitamin K2 + D3 Slowed Artery Calcification ~21% in RCT

BY DR. SYNAPSE ·

A two-year, double-blind trial of 400 people with severe coronary calcification found that high-dose vitamin K2 plus D3 slowed the rise in artery calcium by roughly 21% versus placebo (196 vs 248 AU). Plaque imaging showed no increase in noncalcified plaque, a reassuring sign. But the supplement slowed progression and did not reverse calcium, and the study did not measure heart attacks or deaths. The participants were older (median age 71) with advanced disease, so the results may not apply to everyone. Here is what the DANCODE trial showed, what it did not, and why anyone on warfarin should talk to a doctor first.

Macro photograph at a low 30-degree angle of two tiny mounds on a glossy, saturated teal acrylic surface. The left mound is orange-yellow CoQ10 crystalline powder with visible faceted flakes. The right mound is dull metallic grey selenium granules. A hairline crack runs across the acrylic between them, hinting at the catch. Hard, clean studio light from the upper left throws crisp, short shadows and sparkles on the crystal edges. The background falls softly out of focus, with a thin electric green reflection streaking across the glossy surface. The palette is bold color field: teal against orange, with silver-grey accents. The mood is precise, curious and cautionary, like a lab specimen photographed for a magazine. Photorealistic, shallow depth of field, no text.
longevity

Two Cheap Supplements Cut Heart Deaths by Half. There's a Catch.

BY NOVA CHEN ·

Two inexpensive supplements, CoQ10 and selenium, were linked to a drop in cardiovascular deaths from 12.6% to 5.9% in elderly Swedes. Heart-strain biomarkers and echocardiograms improved as well. But the trial enrolled just 443 people in a selenium-poor country, and it can't say which nutrient did the work. Here's what the KiSel-10 study actually showed, who it may apply to, and the safety limits to know before you try it.

Approach: Macro science. Palette: D, bold color field.

An extreme close-up microscopy-style photograph of a single giant megakaryocyte cell, a large lumpy, lobed cell with a textured, slightly translucent surface, budding off dozens of tiny, smooth, disc-shaped platelets that drift away on fine stringy extensions. The cell and platelets are a warm pearly ivory with subtle coral-pink internal granules and a few small electric green (#00e676) fluorescent specks inside, suggesting recycling vesicles. The backdrop is a saturated, even tomato-red to deep orange color field with a soft gradient. Shot from slightly above at a three-quarter angle, with shallow depth of field so the nearest platelets are crisp and the distant ones melt into soft blur. Lighting is clean, diffuse and glowing from behind, giving gentle rim highlights. Mood: curious, precise, quietly cautionary. No text.
longevity

CoQ10 Calmed 'Old' Platelets in Aged Mice—Here's the Catch

BY NOVA CHEN ·

A new Aging Cell study reports that CoQ10 improved the function of aged megakaryocytes, the bone marrow cells that make platelets, in mice. Treated animals showed reduced platelet aggregation and activation, though platelet counts didn't change. The effect appeared to run partly through COPS3 and autophagy, the cell's recycling system. But this was mouse and cell-line research with no human data and no proof of clot prevention. Here is what it means, what it doesn't, and why people on blood thinners should talk to a doctor first.

This page is available in